What are the latest developments in the search for a cure for Ebola?

  • Context: Medical 
  • Thread starter Thread starter Ygggdrasil
  • Start date Start date
  • Tags Tags
    Antibodies Ebola
Click For Summary

Discussion Overview

The discussion centers around the latest developments in the search for a cure for Ebola, particularly focusing on recent clinical trials of new antibody-based treatments (REGN-EB3 and mAb114) compared to existing therapies (ZMapp and remdesivir). The scope includes preliminary trial results, implications for treatment effectiveness, and logistical challenges in administering these treatments in outbreak situations.

Discussion Character

  • Exploratory
  • Technical explanation
  • Debate/contested

Main Points Raised

  • Some participants report that preliminary data from trials indicate that the new treatments may cure approximately 90% of infected individuals.
  • Others note that the trial was halted early due to the new drugs demonstrating significantly higher effectiveness compared to existing treatments.
  • Concerns were raised about the potential for the virus to mutate and affect the efficacy of monoclonal antibody treatments, particularly for mAb114, which is a single monoclonal antibody.
  • Some participants suggest that REGN-EB3, being a cocktail of three antibodies, may be less susceptible to resistance through mutation.
  • There is acknowledgment of the logistical challenges in administering these treatments quickly in regions affected by violence and distrust.
  • Participants express admiration for the international collaboration involved in the trial, highlighting the roles of various organizations and funding bodies.
  • Concerns were raised about the potential high costs of these biologic treatments and their widespread deployment given the scale of previous outbreaks.

Areas of Agreement / Disagreement

Participants generally agree on the promising nature of the new treatments but express uncertainty regarding the implications of viral mutation and the feasibility of widespread deployment. Multiple competing views remain regarding the effectiveness and accessibility of the treatments.

Contextual Notes

Limitations include the ongoing collection of trial data and the need for formal analysis before definitive conclusions can be drawn about the treatments' effectiveness and deployment strategies.

Who May Find This Useful

This discussion may be of interest to researchers, healthcare professionals, and policymakers involved in infectious disease management, as well as those following developments in Ebola treatment and public health responses.

Ygggdrasil
Science Advisor
Insights Author
Gold Member
Messages
3,753
Reaction score
4,198
TL;DR
Preliminary data from trials of two new treatments for Ebola suggest that they can cure ~90% of infected individuals.
This week, the US National Institutes of Health released an update on a trial in the Democratic Republic of the Congo comparing the effectiveness of two new antibody-based drugs (REGN-EB3 and mAb114) against existing treatments for Ebola (ZMapp and remdesivir). The trial was halted early because the data showed that the new drugs showed they were much more effective than the other treatments, so the NIH will now administer the new treatments to all patients in the study.

Among patients who were brought into treatment centers with low viral loads — which suggested that they had been infected only days before — only 6 percent of those who got Regeneron drug died, and only 11 percent of those who got the Biotherapeutics drug died, Dr. Fauci said.

By contrast, 33 percent of those who received the antiviral drug made by Gilead died, as did 24 percent of those who got ZMapp, an older monoclonal antibody cocktail that was tested briefly during the Ebola outbreak in West Africa in 2014.

The death rate among untreated and unvaccinated patients in this outbreak is thought to be over 70 percent, said Dr. Michael J. Ryan, director of emergency response for the W.H.O.
https://www.nytimes.com/2019/08/12/health/ebola-outbreak-cure.html
Formal analysis and publication of the trial results awaits completion of data collection, which is expected to finish in late Sep/early Oct.

Combined with experimental vaccines, these new treatments can hopefully help contain the current Ebola outbreak and future outbreaks, though quickly administering the drugs to infected individuals remains an issue (especially where there is violence and distrust of governments, as is the case with the currrent outbreak in the DRC).
 
  • Like
  • Informative
Likes   Reactions: Wrichik Basu, berkeman, pinball1970 and 2 others
Biology news on Phys.org
Ygggdrasil said:
Summary: Preliminary data from trials of two new treatments for Ebola suggest that they can cure ~90% of infected individuals.

This week, the US National Institutes of Health released an update on a trial in the Democratic Republic of the Congo comparing the effectiveness of two new antibody-based drugs (REGN-EB3 and mAb114) against existing treatments for Ebola (ZMapp and remdesivir). The trial was halted early because the data showed that the new drugs showed they were much more effective than the other treatments, so the NIH will now administer the new treatments to all patients in the study.https://www.nytimes.com/2019/08/12/health/ebola-outbreak-cure.html
Formal analysis and publication of the trial results awaits completion of data collection, which is expected to finish in late Sep/early Oct.

Combined with experimental vaccines, these new treatments can hopefully help contain the current Ebola outbreak and future outbreaks, though quickly administering the drugs to infected individuals remains an issue (especially where there is violence and distrust of governments, as is the case with the currrent outbreak in the DRC).

The drug is based on monoclonal antibodies according to the link.

Does this mean a major mutation in the virus could affect the treatment?
 
  • Like
Likes   Reactions: atyy
pinball1970 said:
The drug is based on monoclonal antibodies according to the link.

Does this mean a major mutation in the virus could affect the treatment?
The drugs are indeed monoclonal antibodies, and like all drugs, could be subject to resistance through mutation of the virus. This is most true of mAB114, which is a single monoclonal antibody (https://www.ncbi.nlm.nih.gov/pubmed/26917593?dopt=Abstract). REGN-EB3 is a cocktail of three different antibodies (https://www.ncbi.nlm.nih.gov/pubmed/29860496) and it would presumably be much more difficult for the virus to acquire multiple mutations simultaneously to gain resistance to all three.

Because the epitopes targeted by the antibodies are known, monitoring the virus through DNA sequencing could likely help diagnose the arrival of resistant stains.
 
  • Like
  • Informative
Likes   Reactions: atyy, BillTre and pinball1970
Ygggdrasil said:
Summary: Preliminary data from trials of two new treatments for Ebola suggest that they can cure ~90% of infected individuals.

The trial was halted early because the data showed that the new drugs showed they were much more effective than the other treatments, so the NIH will now administer the new treatments to all patients in the study.
Yeah, that would suck to be on the wrong end of that double-blind study!

Glad they stopped early and administered the drug to all. What a promising advance! :smile:
 
berkeman said:
Yeah, that would suck to be on the wrong end of that double-blind study!

Glad they stopped early and administered the drug to all. What a promising advance! :smile:
Underreported in West and a horrific disease. Not many grade 4 out there, Lassa is one.
Hats off to the guys who try and manage this in the field. Medecins sans frontieres for example.
 
Last edited:
  • Like
Likes   Reactions: atyy, Klystron, BillTre and 1 other person
pinball1970 said:
Underreported in West and a horrific disease. Not many grade 4 out there, Lassa is one.
Hats off to the guys who try and manage this in the field. Medicins sans frontiers for example.

MSF played a key role in the trial as the trials were carried out in Ebola Treatment centers run by staff from the DRC Institut National de Recherche Biomédicale (INRB); the DRC Ministry of Health; and three medical humanitarian organizations: the Alliance for International Medical Action (ALIMA), the International Medical Corps (IMC), and Médecins Sans Frontières (MSF).

Indeed, the study is a good example of the usefulness of international public-private partnerships as the study is co-sponsored and funded by the DRC's INRB and the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health; carried out by an international research consortium coordinated by the World Health Organization (WHO); and supported by four pharmaceutical companies (MappBio, Gilead, Regeneron, and Ridgeback Biotherapeutics).

Hats off to all entities involved.
 
  • Like
  • Informative
Likes   Reactions: atyy, Klystron, pinball1970 and 1 other person
This sounds very impressive but I expect that these drugs like all of the biologics will be horrendously expensive. The trial was supported by the drug companies and others but I wonder if it will be possible to deploy these drugs widely. The current outbreak and the previous one in west Africa have both had thousands of confirmed cases.
 
Wow! It makes me cry. I did find this article ~

At 1-year mark, we mourn the lives lost to Ebola, and call for solidarity
Joint statement by heads of agencies on the Ebola outbreak in the Democratic Republic of the Congo
31 July 2019
Statement

New York, Geneva, Kinshasa, Rome

“Tomorrow, 1 August, marks one year since the Government of the Democratic Republic of the Congo (DRC) declared an outbreak of the Ebola virus disease in North Kivu province of the DRC. Two weeks ago, it was declared a public health emergency of international concern.

“Just yesterday, a new case of the disease was confirmed in Goma, with the patient later dying – the second case to be confirmed this month in the city of around 1 million people. This latest case in such a dense population center underscores the very real risk of further disease transmission, perhaps beyond the country’s borders, and the very urgent need for a strengthened global response and increased donor investment.
“In the last year, there have been more than 2,600 confirmed cases, including more than 1,800 deaths in parts of Ituri and North Kivu provinces. Almost one in three ‘cases’ is a child. Every single ‘case’ is someone who has gone through an unimaginable ordeal. More than 770 have survived.
“The disease is relentless and devastating.

[. . .]

“At this critical juncture, we reaffirm our collective commitment to the people of the DRC; we mourn for those we have lost; and we call for solidarity to end this outbreak.”

Statement from WHO Director-General Dr Tedros Adhanom Ghebreyesus, UN Under-Secretary-General for Humanitarian Affairs and Emergency Relief Coordinator Mark Lowcock, UNICEF Executive Director Henrietta Fore, and World Food Programme Executive Director David Beasley
https://www.who.int/news-room/detai...-mourn-the-lives-lost-and-call-for-solidarity
 

Similar threads

  • · Replies 12 ·
Replies
12
Views
3K
Replies
11
Views
2K
  • · Replies 1 ·
Replies
1
Views
2K
  • · Replies 74 ·
3
Replies
74
Views
12K
Replies
1
Views
2K
  • · Replies 21 ·
Replies
21
Views
4K
  • · Replies 2 ·
Replies
2
Views
4K
  • · Replies 12 ·
Replies
12
Views
6K
  • · Replies 3 ·
Replies
3
Views
6K
  • · Replies 1 ·
Replies
1
Views
12K